CURRICULUM VITAE

Christin Rogers, Pharm.D., BCPS

PERSONAL INFORMATION

Office Address:
Beth Israel Deaconess Medical Center
One Deaconess Rd
Boston, MA 02215
Phone: (617) 754-3823
Fax: (617) 754-3833
Pager: (617) 632-page x35909
E-mail: crogers3@bidmc.harvard.edu

Licensure:
Registered Pharmacist
State of Massachusetts: # 26156, October 2004

Board Certification:
Board Certified Pharmacotherapy Specialist
December 2006

EDUCATION

DOCTOR OF PHARMACY — Sept.1995-June 2001
Bouve' College of Pharmacy and Health Sciences
Northeastern University, Boston, Massachusetts

ASHP ACCREDITED PHARMACY PRACTICE RESIDENCY — July 2001- July 2002
University of Colorado Health Sciences Center
Denver, Colorado

TRANSPLANT PHARMACY RESIDENCY — Aug 2002- Aug 2003
University of Cincinnati, Department of Surgery, Division of Transplantation
Cincinnati, Ohio

TRANSPLANT PHARMACOTHERAPY RESEARCH FELLOWSHIP — Aug 2003- Aug 2004
University of Cincinnati, Department of Surgery, Division of Transplantation
Cincinnati, Ohio

PROFESSIONAL EXPERIENCE

CLINICAL PHARMACY COORDINATOR- SOLID ORGAN TRANSPLANT — Aug 2004- Present
Beth Israel Deaconess Medical Center
Boston, Massachusetts

ADJUNCT CLINICAL ASSISTANT PROFESSOR — Feb 2007 - Present
DEPARTMENT OF PHARMACY PRACTICE
Northeastern University – Bouve' College of Health Sciences
Boston, MA

CLINICAL PHARMACIST — Sept. 2001- July 2002
University of Colorado Hospital
Denver, Colorado

TEACHING EXPERIENCE

Preceptor for Solid Organ Transplant Rotation — Aug. 2004- Present
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Clinical Instructor — July 2001-June 2002
University of Colorado Health Sciences Center, School of Pharmacy
Denver, Colorado

Preceptor for first year pharmacy students' experiential portfolios — Oct. 2001-June 2002
University of Colorado Health Sciences Center, School of Pharmacy
Denver, Colorado

Teaching Assistant for Pharmacy Skills Lab — Oct. 2001-June 2002
University of Colorado Health Sciences Center, School of Pharmacy
Denver, Colorado

Co-preceptor for Internal Medicine externship at University Hospital — Oct. 2001/Feb.2002
University of Colorado Health Sciences Center, School of Pharmacy
Denver, Colorado

INVITED PRESENTATIONS

Clinical Considerations for Appropriate Dispensing of Intravenous Immunoglobulin
- BIDMC Pharmacy Department — Dec 2008

Drug Disposition and Metabolism in Liver Disease — Nov 2008
- Hepatology Grand Rounds

Management of Drug Interactions in Transplant Patients — July 2008
- Nephrology resident teaching seminar

Optimizing Immunosuppression in the Outpatient Setting — May 2008
- Podcast for BIDMC transplant website

Impact of Immunosuppression on Hepatitis C recurrence — Mar 2008
- Hepatology Grand rounds

Management of immunosuppression in the liver transplant population — Nov 2007
- Hepatology Grand rounds

Transplant Nursing Symposium — Nov 2007
- CE program to transplant and SICU nurses at BIDMC

Optimizing Cellcept Immunosuppression — Oct 2007
- Invited lecture for transplant Nursing staff

Hepatitis B and C; What every pharmacist needs to know — Aug 2007
- CE program for Boston area pharmacists

Management of Hepatitis B in the Posttransplant Setting Oct 2006
- Invited faculty at 2006 ACCP Annual Meeting, St Louis, MO

Transplant Nursing Symposium Nov 2006
- CE program to transplant and SICU nurses at BIDMC

Transplant Pharmacology: Keys to Medication Management in Organ Transplant Recipients
- CE program for Boston area pharmacists May 2006

Current Trends in Immunosuppressive Therapy
- CE program for Boston area nephrologists Sept 2005

What's Hot, What's New In Immunosuppression May 2005
- Invited faculty at 2005 NKF Annual Meeting, Washington DC

Challenges in Drug Therapy in the HIV + Transplant Recipient Feb. 2005
- CE program for Boston Hospital Pharmacists

Update in Solid Organ Transplantation Nov. 2004
- CE program for Beth Israel Deaconess Medical Center Pharmacy Department

Issues in Transplant Patients; Pharmacotherapy and Clinical Management April 2004
- Presented at the Ohio Pharmacists Association Annual Meeting

Pharmacology of Immunosuppressants July 2003
- Presented to residents and fellows at The University of Cincinnati transplant teaching conference

PUBLICATIONS

Articles

1. DeSalvo D, Roy-Chaudhury P, Merchen T, Konijetti K, Gupta M, Boardman R, **Rogers C**, Hanaway M, Buell J, Konoplev K, Smith R, Woodle ES, Peddi R. West Nile Virus Encephalitis in Organ Transplant Recipients: Another High Risk Group for Meningoencephalitis and Death? *Transplantation. 2004 Feb 15;77(3):466-9.*

2. **Rogers CC**, Alloway RR, Boardman RE, Trofe J, Hanaway MJ, Alexander JW, Roy-Chaudhury P, Buell JF, Thomas MJ, Cardi M, Susskind B, and Woodle ES. Global Cardiovascular Risk Under Steroid Cessation Decreases Progressively in the First Year Post Transplant. Transplant Proc. 2005 Mar;37(2):812-13

3. Alloway RR, Hanaway MJ, Trofe J, Boardman R, **Rogers CC**, Buell JF, Munda R, Alexander JW, Thomas MJ, Roy-Chaudhury P, Cardi M, Woodle ES. A prospective, pilot study of early corticosteroid cessation in high-immunologic-risk patients: the Cincinnati experience. Transplant Proc. 2005 Mar;37(2):802-3.

4. **Rogers CC**, Hanaway MJ, Alloway RR, Alexander JW, Boardman RE, Trofe J, Gupta M, Merchen T, Buell JF, Cardi M, Roy-Chaudhury P, Succop P, and Woodle ES. Corticosteroid avoidance ameliorates lymphocele formation and wound healing complication associated with sirolimus therapy. Transplant Proc. 2005 Mar;37(2):795-7.

5. Boardman R, Trofe J, Alloway R, **Rogers C**, Roy-Chaudhury P, Cardi M, Safdar S, Groene B, Buell J, hanaway M, Thomas M, Alexander W, Munda R, Woodle ES. Early steroid withdrawal does not increase risk for recurrent focal segmental glomerulosclerosis. Transplant Proc. 2005 Mar;37(2):817-18.

6. Woodle ES, Susskind B, Alloway RR, Hanaway MJ, Thomas M, Buell J, Alexander JW, Roy-Chaudhury P, Succop P, Cardi M, Boardman R, **Rogers C**. Histocompatibility testing predicts acute rejection risk in early corticosteroid withdrawal regimens. Transplant Proc. 2005 Mar;37(2):809-11.

7. Boardman RE, Alloway, RR, **Rogers, CC**, Clippard, M, Gupta M, Merchen T, Metze T, Suskind B, Trofe J, Peddi V, Woodle, ES. African American Renal Transplant Recipients: Experience with Early Corticosteroid Cessation Under Modern Immunosuppression. Am J Transplant. 2005 Feb(2):356-65

8. Page RL, Klem P, **Rogers CC**. Probable Elevation of Tacrolimus Trough Concentrations with Concomitant Metronidazole Therapy. Ann Pharmacother. 2005 Jun;39(6):1109-13

9. **Rogers CC**, Alloway RR, Hanaway MJ, Buell JF, Alexander JW, Gupta M, Merchen TD, Thomas MJ, Roy-Chaudhury P, Trofe J, Cardi M, Munda R and Woodle ES. Impact of Early Corticosteroid Cessation on Body Weight Alterations in Renal Transplant Recipients. Transplantation 2005 Jul 15;80(1):26-33

10. **Rogers CC**, Alloway RR, Alexander JW, Cardi MA, Trofe J, Woodle ES, Vinks AA. Pharmacokinetics of Mycophenolic Acid, Tacrolimus and Sirolimus after Gastric Bypass Surgery in End Stage Renal Disease and Transplant Patients: A Pilot Study. Clin Transplant. 2008 May-Jun;22(3):281-91.

11. **Rogers CC**, Johnson SR, Mandelbrot DA, Pavlakis M, Horwedel T, Karp SJ, Egbuna O, Rodrigue JR, Chudzinski RE, Golfarb-Rumyantzev AS, Hanto DW and Curry MP. Timing of Sirolimus Conversion Influences Recovery of Rena Function in Liver Transplant Recipients.
    - *Submitted for publication – Clinical Transplantation*

Book Chapters

Gabardi S, Baroletti SA, McDevitt LM, Saxer SB, Vaughn FM, Rogers CC. A Clinicians Guide to Donation and Transplantation, Chapter 23 - Pharmaceutical Care

Abstracts

1. **Rogers C**, Barin B, Johnson S, Wong M, Stablein D, Stock P, Frasetto L, Hanto D, and Roland M. Rapamycin fails to yield a renal sparing effect in HIV+ transplant recipients. Poster presentation – American Transplant Congress 2009. Boston, MA, May 30-June 3 2009.

2. **Rogers CC**, Horwedel T, Asipenko N, Pavlakis M, Egbuna O, Johnson S, Karp S, Khwaja K, Chudzinski R, Hanto DW and Mandelbrot D. Efficacy of Low Dose Thymoglobulin Induction for Renal Transplantation in the Setting of Early Steroid Withdrawal. Poster presentation – American Transplant Congress 2008. Toronto, ON, May 30-June 4 2008.

3. **Rogers C**, Johnson S, Gribbons M, Khwaja K, Karp S, Egbuna O, Mandelbrot D, Pavlakis M, Hanto D, Curry M. Timing of sirolimus conversion influences recovery of renal function in liver transplant recipients. Oral presentation- American Transplant Congress 2007, San Francisco, CA, May 5-9, 2007

4. **Rogers C**, Bain B, Johnson S, Wong M, Stablein D, Stock P, Frasetto L, Hanto D, Roland M. Renal sparing effects of rapamycin in HIV+ transplant recipients. Oral Presentation - American Transplant Congress 2007. San Francisco, CA, May 5-9, abstract #57

5. **Rogers CC**, Johnson S, Snow E, Hanto DW, Khwaja K, Karp S, Egbuna O, Mandelbrot D, Pavlakis M and Curry M. Early Sirolimus Conversion is Superior to late Sirolimus Conversion in Reversing Renal Dysfunction in Liver Transplant Recipients. Oral Presentation- World Transplant Congress 2006, Boston, MA , Poster Presentation ACCP Annual Meeting 2006, St Louis

6. Khwaja K, Johnson S, Pavlakis M, Karp S, **Rogers C**, Mandelbrot D, Monaco A, Hanto D. Prednisone-free Immunosuppression in Kidney Transplant Recipients from Donors after Cardiac Death. Poster Presentation- World Transplant Congress 2006, Boston, MA

7. Egbuna O, Johnson S, Pavlakis M, Khwaja K, Karp S, **Rogers C**, Curry M, Snow E, Hanto D, Mandelbrot D. Efficacy and Safety of Conversion from Calcineurin Inhibitors to Sirolimus After Early corticosteroid Withdrawal in Kidney Transplantation. Poster Presentation- World Transplant Congress 2006, Boston, MA

8. **Rogers CC**, Alloway RR, Alexander JW, Austin J, Boardman RE, Cardi MA, Goel S, Goodman H, Huang S, Safdar S, Trofe J, Woodle ES, Vinks AA. A Pilot Study to Determine the Pharmacokinetics of Various Immunosuppressants in Pre-Renal Transplant Recipients Who Have Undergone Gastric Bypass Surgery. Oral Presentation- American Transplant Congress 2005, Seattle , WA

9. **Rogers CC**, Alloway RR, Hanaway MJ, Buell JF, Alexander JW, Gupta M, Merchen TD, Thomas MJ, Roy-Chaudhury P, Trofe J, Cardi M, Munda R and Woodle ES. Impact of Early Corticosteroid Cessation on Body Weight Alterations in Renal Transplant Recipients. Oral Presentation- American Transplant Congress 2004, Boston , MA. Poster Presentation- International Transplant Congress 2004, Vienna, Austria

10. **Rogers CC**, Alloway RR, Boardman RE, Trofe J, Hanaway MJ, Alexander JW, Roy-Chaudhury P, Buell JF, Thomas MJ, Cardi M, Susskind B, and Woodle ES. Global Cardiovascular Risk Under Steroid Cessation Decreases Progressively in the First Year Post Transplant. Oral Presentation- American Transplant Congress 2004, Boston , MA. Poster Presentation- International Transplant Congress 2004, Vienna, Austria

11. **Rogers CC**, Alexander JW, Alloway RR, Metze TJ, Boardman RE, Trofe J, Gupta M, Merchen T, Hanaway MJ, Buell JF, Cardi M, Roy-Chaudhury P, Woodle ES. Corticosteroid Avoidance Ameliorates Lymphocele Formation and Wound Healing Complications Associated With Sirolimus Therapy: 2 year Follow-Up in 109 Patients. Oral Presentation- American Transplant Congress 2004, Boston , MA. Oral Presentation- International Transplant Congress 2004, Vienna, Austria, Oral Presentation- Annual Transplant Fellows Conference, 2004

12. **Rogers CC,** Beebe TM, Hanaway MJ, Thomas MJ, Gross TG, Rudich SM, First MR, Alloway RR, Trofe J, Woodle ES and Buell JF. Immunomodulation Impacts Survival of Donor Transmitted Malignancies. Poster Presentation- American Transplant Congress 2004, Boston , MA

13. Alloway RR, Trofe J, Boardman RE, **Rogers CC**, Kidd M, Buell JF, Hanaway MJ, Munda R, Alexander JW, Thomas MJ, Roy-Chaudhury P, Cardi MA, Austin J, Goel S, Safdar S, Huang S, Woodle ES. A prospective pilot study of early corticosteroid elimination under modern immunosuppression in patients at high immunologic risk: One-year results. Poster Presentation- American Transplant Congress 2004, Boston , MA

14. Boardman RE, Trofe T, Alloway RR, **Rogers C**, Roy-Chaudhury P, Cardi MA, Safdar S, Buell JF, Hanaway MJ, Thomas M, Alexander JW, Munda R, Woodle ES. Early steroid withdrawl does not increase risk for recurrent focal segmental glomerulosclerosis. Oral Presentation- American Transplant Congress 2004, Boston , MA

15. Boardman RE, Trofe J, Alloway RR, **Rogers C**, Roy-Chaudhury P, Cardi M, Safdar S, Woodle ES. Bone pain in renal transplantation: Does sirolimus play a role? Oral Presentation- American Transplant Congress 2004, Boston , MA

16. Trofe J, Woodle ES, Gordon J, Wadih G, Succop P, Alloway RR, Mutema G, Cavallo T, Heffelfinger S, Cardi MA, Austin J, Goel S, Safdar S, Huang S, Raabe S, Munda R, Buell J, Hanaway M, Alexander JW, Boardman R, **Rogers C**, Kidd M, Jain A, Berilla E, Demmey A, Khalili K, Roy-Chaudhury P. Histologic grading of PVN biopsies: Correlation with viral load monitoring and renal function. Oral Presentation- American Transplant Congress 2004, Boston , MA

17. Woodle ES, Susskind B, Alloway RR, Hanaway MJ, Thomas M, Alexander JW, Merchen T, Gupta M, Succop P, Roy-Chaudhury P, Cardi M, Boardman R, **Rogers C**. Histocompatibility testing predicts acute renal allograft rejection risk in early corticosteroid cessation (ECS) regimens. Poster Presentation- American Transplant Congress 2004, Boston , MA.

18. **Rogers CC**, Gross TG, Hanaway MJ, First MR, Trofe J, Alloway RR, Beebe TM, Woodle ES, Sethuraman G, Buell JF. De Novo Renal Cell Carcinoma in Solid Organ Transplant Recipients: Site of Origin (Native vs. Transplanted Kidney) Influences Biologic Behavior. Oral Presentation- American Transplant Congress 2003, Washington DC

19. **Rogers CC**, Alexander JW, Metze T, Boardman R, Trofe J, Gupta M, Merchen T, Hanaway MJ, Buell JF, Cardi M, Roy-Chaudhury P, Peddi VR, Goodman H, Sethuraman G, Woodle ES. Corticosteroid Avoidance Ameliorates Lymphocele Formation and Wound Healing Complications Associated with Sirolimus Therapy. Poster Presentation- American Transplant Congress 2003, Washington DC
20. **Rogers CC**, Alloway RR, Buell JF, Alexander JW, Gupta M, Sethuraman G, Metze T, Goodman H, Alonzo MA, Cardi M, Munda R, Woodle ES. Body Weight Alterations Demonstrate Distinct Patterns in Renal Transplant Recipients Treated with Steroid-Free and Steroid Based Immunosuppression. Poster Presentation- American Transplant Congress 2003, Washington DC

21. **Rogers CC**, Alloway R, Boardman R, Trofe J, Hanaway M, Alexander J, Peddi R, Roy-Chaudhury P, Cardi M, Susskind B, Woodle ES. Cardiovascular Risk Alterations With Early Corticosteroid Cessation Under Modern Immunosuppression: Objective Assessment By Framingham Risk Analysis. Poster Presentation- American Transplant Congress 2003, Washington DC

22. Boardman RE, Alloway, RR, **Rogers, C**, Clippard, M, Gupta M, Merchen T, Metze T, Suskind B, Trofe J, Peddi V, Woodle, ES. African American Renal Transplant Recipients: Experience with Early Corticosteroid Cessation Under Modern Immunosuppression. Oral Presentation- American Transplant Congress 2003, Washington DC

23. Metze T, Alexander JW, AllowayRR, Clippard M, **Rogers C**, Susskind B, Alonzo M, Peddi VR, Roy-Chaudhury P, Woodle ES. Early Steroid Withdrawal in Renal Transplantation: Elderly Patients and Recipients of HLA Matched Kidneys have Lower Rejection Rates Compared to “Normal Risk” Patients. Oral Presentation- American Transplant Congress 2003, Washington DC

24. Woodle ES, Vicenti F, Lorber M, Grisch A, Washburn K, Matas A, Gallichio M, **Rogers CC**. Influence of Early (5 Day) Corticosteroid Cessation on Wound Complications Associated with Sirolimus: Results from a Multicenter Trial. Poster Presentation- American Transplant Congress 2003, Washington DC

25. Trofe J, Gordon J, Roy-Chaudhury P, Mutema G, Cavallo T, Buell JF, Alloway RR, Safdar S, Cardi M, Hanaway MJ, Austin J, Goel S, Huang S, Peddi VR, **C Rogers**, Boardman R, Munda R, Alexander JW, Khalili K, Woodle ES. Correlation of BK Viral Load Monitoring and Host Immune Responses in Post-Transplant Polyomavirus Nephropathy. Poster Presentation- American Transplant Congress 2003, Washington DC

26. Trofe J, Roy-Chaudhury P, Gordon J, Mutema G, Cavallo T, Cardi M, Austin J, Goel S, **Rogers C**, Boardman R, Clippard M, Alloway RR, Alexander JW, Metze T, Goodman H, Hanaway MJ, Munda R, Buell JF, Peddi VR, Safdar S, Huang S, Fidler J, Khalili K, Woodle ES. Early Steroid Cessation / Avoidance Regimens are Associated with a Lower Incidence of Polyomavirus Nephropathy Compared to Steroid Based Immunosuppression in Kidney Transplant Recipients. Poster Presentation- American Transplant Congress 2003, Washington DC

27. DeSalvo D, Roy-Chaudhury P, Merchen T, Konijetti K, Gupta M, Boardman R, **Rogers C**, Hanaway M, Buell J, Konoplev K, Smith R, Woodle ES, Peddi R. West Nile Virus Encephalitis in Organ Transplant Recipients: Another High Risk Group for Meningoencephalitis and Death? Oral Presentation- American Transplant Congress 2003, Washington DC

28. Roy-Chaudhury P, **Rogers C**, McKee L, Armstrong J, Alloway R, Heffelfinger S, Smith R, Peddi R, Kelly B, Cavallo T, Woodle ES, Mutema G. Is Glomerular Deposition of C4d a Prognostic Marker in Chronic *A*llograft Dysfunction*?* Poster Presentation- American Transplant Congress 2003, Washington DC

29. Prabir Roy-Chaudhury, **C Rogers**, MR First, VR Peddi, ES Woodle, R Smith, G Mutema, T Cavallo, A Govil, J Armstrong, L McKee, S Heffelfinger. C4d deposition in chronic allograft dysfunction. Poster presentation American Society of Nephrology (ASN) Renal Week 2002, Philadelphia, PA

30. **Rogers CC**, Klem PM, Janni A. Evaluation of Dyslipidemia Management in an Outpatient Renal Transplant Clinic. Poster presentation- 36th ASHP Midyear Clinical Meeting, New Orleans, LA

31. **Rogers CC**, Karish SB, Bursich N, Ingenito S. A Pharmacoeconomic Analysis of Raloxifene vs. Alendronate for the Prevention of Hip and Vertebral Fractures in Postmenopausal Women. Poster presentation- 35th ASHP Midyear Clinical Meeting, Las Vegas, NV

RESEARCH ACTIVITIES

"Pharmacokinetics of Immunosuppressants in Transplant Patients Who Have Undergone Gastric Bypass Surgery" Funded by American College of Clinical Pharmacy Research Institute Grant.- **Co-Investigator**

"Renal sparing effects of Rapamycin in HIV+ transplant recipients" Funded by NIH– **Co-Investigator**

"Timing of sirolimus conversion influences recovery of renal function in liver transplant recipients" – **Co-Investigator**

"Efficacy of Low Dose Thymoglobulin Induction for Renal Transplantation in the Setting of Early Steroid Withdrawal" – **Co-Investigator**

"Evaluation of the effects of sirolimus on liver fibrosis in hepatitis C positive liver transplant recipients" – **Co-Investigator**

"A single-blind, placebo-controlled, safety and tolerability study of the effects of carbon monoxide for inhalation in patients receiving kidney transplantation" - **Co-Investigator**

"A Multicenter, Randomized, Double-Blind, Placebo-controlled, Multiple Dose Study of the Safety, Tolerability and Population Pharmacokinetics of CMX001 in Post-transplant Subjects with BK Virus Viruria" **Co-Investigator**

"Solid Organ Transplantation in HIV: A multi-center study" – **Co- Investigator**

"Planned Transition to Sirolimus-based Therapy versus Continued Tacrolimus-based Therapy in Renal Allograft Recipients" – **Co-Investigator**

"A Phase II, Open-Label, Multi-Center Prospective, Conversion Study in Stable Liver Transplant Patients to Compare the Pharmacokinetics of LCP-Tacro Tablets Once-A-Day to Prograf® Capsules Twice-A-Day" Funded by Lifecycle Pharma **Co-Investigator**

"A Phase 3, Open-label, Multicenter, Prospective, Randomized Study of the Efficacy and Safety of Conversion from Prograf® Capsules Twice Daily to LCP Tacro™ Tablets Once Daily for the Prevention of Acute Allograft Rejection in Stable Kidney Transplant Patients" Funded by Lifecycle Pharma – **Co-Investigator**

"A prospective, open-label, multi-center, randomized trial of the efficacy and safety of a long term calcineurin inhibitor free maintenance regimen with mycophenolate mofetil and sirolimus in recipients of an orthotopic liver transplant" Funded by Roche Pharmaceuticals- **Co-Investigator**

"A Phase IIB, Randomized, Multicenter, Open-label, Concentration-controlled, Safety Study of ISA247 and Tacrolimus (Prograf®) In *De novo* Renal Transplant Patients (ISA05-01)" Funded by Isotechnica **– Co-Investigator**

"B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients who Develop Early de novo Anti-HLA Alloantibodies will Result in Inhibition of Alloantibody Production and Attenuation of Chronic Humoral Rejection" Funded by the NIH- **Co-Investigator**

" A 12 month open-label, randomized, multicenter, sequential cohort, dose finding study to evaluate the efficacy, safety and tolerability or oral AEB071 verses tacrolimus in combination with myfortic®, Simulect® and corticosteroids in *de novo* adult renal transplant recipients"- Funded by Novartis Pharmaceuticals **– Co- Investigator**

"An open label, prospective, randomized, controlled, multi-center study assessing fixed dose vs concentration controlled CellCept® regimens for patients following a single organ renal transplantation in combination with full dose and reduced dose calcineurin inhibitors" Funded by Roche Pharmaceuticals- **Co-Investigator**

"A Randomized, Placebo Controlled, Double-Blind Comparative Study Evaluating the Effect of Ramipril On Urinary Protein Excretion in Maintenance Renal Transplant Patients Converted to Sirolimus" **Co-Investigator**

"Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial-Extended Criteria Donors" Funded by Bristol Myers Squibb **– Research Assisstant**

"Immune Response to Influenza Vaccination in Renal Transplant Recipients Taking Rapamycin" Funded by Wyeth Pharmaceuticals-**Research Assisstant**

”An Open-label, Concentration Controlled, Randomized, 12 Month Study of Prograf, Rapamune, Corticosteroids Compared to Cyclosporine and Rapamune and Corticosteroids in High Risk Renal Allograft Recipients.” Funded by Wyeth Ayerst Pharmaceuticals. **Research Assisstant**

“A Randomized, Open-Label, Comparative Evaluation of Conversion from Calcineurin Inhibitor Treatment to Sirolimus Treatment Verses Continued Calcineurin Inhibitor Treatment in Liver Allograft Recipients Undergoing Maintenance Therapy.” Funded by Wyeth Ayerst Pharmaceuticals. **Research Assisstant**

“A Phase II, Open-Label, Multicenter Study to Assess the Pharmacokinetics, Safety and Tolerability in Stable Kidney Transplant Patients converted from a Prograf Based Immunosuppression Regimen to a Modified Release (MR) Tacrolimus Based Immunosuppression Regimen.” Funded by Fujisawa. **Research Assisstant**

“A Phase II, Open-Label, Multicenter Study to Assess the Pharmacokinetics, Safety and Tolerability in Stable Liver Transplant Patients converted from a Prograf Based Immunosuppression Regimen to a Modified Release (MR) Tacrolimus Based Immunosuppression Regimen.” Funded by Fujisawa. **Research Assisstant**

“A Phase II, Open-Label, Multicenter Study to Assess the Pharmacokinetics, Safety and Tolerability in Stable Heart Transplant Patients converted from a Prograf Based Immunosuppression Regimen to a Modified Release (MR) Tacrolimus Based Immunosuppression Regimen.” Funded by Fujisawa. **Research Assisstant**

“A Prospective, Randomized, Multicenter Trial of Early Corticosteroid Cessation vs. Long Term Maintenance Corticosteroid Therapy in Primary Renal Allograft Recipient’s treatment with Tacrolimus and Mycophenolate Mofetil.” Funded by Fujisawa Pharmaceuticals. – **Research Assisstant**

“A Prospective Pilot Study of Early Corticosteroid Cessation with Zenapax, Prograf, Cellcept, and Rapamune in High Immunologic Risk Renal Transplant Recipients.” Funded by Roche Laboratories. **Research Assisstant**

“A Prospective Pilot Study of Corticosteroids Avoidance with Prograf, Cellcept, and Rapamune, that Avoids Induction Therapy in Renal Transplant Patients” Funded by Wyeth Ayerst Pharmaceutical Company. **Research Assisstant**

“An Open-Label Study to Evaluate the Safety of Early (5 day) Steroid Cessation in De Novo Renal Allograft Recipients Treated with Simulect Induction and Prograf in Combination with Rapamune.” Funded by Wyeth Ayerst Pharmaceutical Company **Research Assisstant**

“A Multicenter, Randomized, Partially-blinded Study of the Safety and Efficacy of FTY720 Combined with Corticosteroids and Full or Reduced Dose Neoral in De Novo Adult Renal Transplant Recipients.” Funded by Novartis Pharmaceutical Company. **Research Assisstant**

“Corticosteroid-free, Calcineurin-sparing Immunosuppression Protocol for HLA-Identical living Donor renal Transplant Recipients”. Funded by Roche Laboratories. **Research Assisstant**

"A Randomized, Open-Label, Comparative Evaluation of Conversion from Calcineurin Inhibitors to Sirolimus versus Continued Use of Calcineurin Inhibitors in Renal Allograft Recipients.” Funded by Wyeth Ayerst Pharmaceutical Company. **Research Assisstant**

"Open-Label, Randomized, Prospective Multicenter Study to Compare the Efficacy and Safety Among Three Immunosuppressant Regimens in Patients Receiving a Liver Transplant for End-Stage Liver Disease Caused by Chronic Hepatitis C Infection." Funded by Roche Laboratories. **Research Assisstant**

"Rapamune Outcomes Assessment Registry" Funded by Wyeth Ayerst Pharmaceutial Company **Research Assisstant**

"A Single Center, Pilot Study of Corticosteroid Discontinuation in Liver Transplant Recipients Utilizing a Tacrolimus / Mycophenolate Mofetil Based Maintenance Immunosuppression Protocol." Funded by Fujisawa Pharmaceuticals **Research Assisstant**

" An Open Label Randomized Single Center Study to Evaluate the Efficacy of Early Calcineurin Inhibitor Withdrawal in Recipients of Primary Renal Allografts Maintained Long-term on Mycophenolate Mofetil and Sirolimus Without Prednisone." Funded by Roche Laboratories. **Research Assisstant**

"A Phase III, Randomized, Open-label, Comparative, Multicenter Study to Assess the Safety and Efficacy of Prograf/MMF, Modified Release Prograf/MMF and Neoral/MMF in De Novo Kidney Transplant Recipients". Funded by Fujisawa healthcare Inc. **Research Assisstant**

"FK 778 De Novo Renal Transplant Study". Funded by Fujisawa Healthcare Inc.. **Research Assisstant**
"Randomized, Prospective, Phase II Study Comparing Thymoglobulin in a Rapid Discontinuation of Corticosteroids Protocol with Standard CorticosteroidTherapy in Living Donor Renal Transplantation Using Mycophenolate Mofetil and Tacrolimus Maintenance Therapy". Funded by Sangstat Medical Corporation. **Research Assisstant**

"Evaluation of Immune Globulin Intravenous, (Human), 10% , Manufactured by Chromotography Process (IGIV-C 10%), as an Agent to Reduce Anti-HLA Antibodies and Improve Transplantation Results in Cross Match Positive Living Donor Kidney Allograft Recipients" Funded by NIH. **Research Assisstant**

"Extension: A Prospective Pilot Study of Corticosteroid Avoidance with Prograf, Cellcept and Rapamune that Avoids Induction Therapy in Renal Transplant Patients" Funded by Wyeth Ayerst Pharmaceutical Company. **Research Assisstant**

"Clinical, Immunologic, and Pharmacologic Consequences of Kidney and Liver Transplantation in People with HIV Infection." Funded by NIH. **Research Assisstant**

FUNDING

ACCP Roche Laboratories Transplantation Fellowship- $ 27,500

- Funding to support pharmacokinetic study of immunosuppressants in transplant patients who have undergone gastric bypass surgery

EDITORIAL REVIEW

Reviewer for Pharmacotherapy	2008 - present
Reviewer for Annals of Pharmacotheray	Sept 2003
Reviewer for Progress in Transplantation	Oct. 2003

COMMUNITY SERVICE

Habitat for Humanity – Assisted in building a house for a family in need Oct. 2007

University of Colorado Hospital Smoking Cessation Program Jan. 2002-March 2002
- Led group discussions on various smoking cessation methods

Alcohol and Marijuana: Not a Good Combination. Oct. 2001
- Presentation to 5th and 6th grade class at Westridge Elementary School

Lakewood, Colorado for D.A.R.E.'s Red Ribbion Week

Diabetes Screening Day at Whittier Street Health Clinic Nov. 2000
- Screened walk-in patients for diabetes

National Pharmacy Week at Northeastern University Oct. 2000
- Conducted osteoporosis screening and handed out health care pamphlets

PROFESSIONAL AFFILIATIONS

American Society of Health System Pharmacists 1999- present
American College of Clinical Pharmacy 2002- present
American Society of Transplantation 2003- present
Transplantation Society 2004-present
Colorado Pharmacists Society 2001-2002

PROFESSIONAL APPOINTMENTS

American College of Clinical Pharmacy
- Transplant and Immunology Practice Research Network – Secretary 2008-2009

American Society of Transplantation
- Transplant Pharmacist Community of Practice – Founder and Chair 2008-2012

AWARDS AND HONORS

Beth Israel Deaconess Medical Center - Out of the Box Award – Recognition for development of Transplant Self-Medication Program
Deans List – Northeastern University
Dean Constantine N. Meriano Alumni Senior Class Award
ACCP Roche Transplantation Research Fellowship Award
Poster of Distinction- American Transplant Congress 2004